Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study

Fig. 2

Treatment response and duration. a Best percentage changes from baseline in target lesions per RECIST v1.1; b best percentage changes from baseline in target lesions per mRECIST; c treatment exposure and response duration per RECIST v1.1; and d treatment exposure and response duration per mRECIST

Back to article page